NASDAQ · OTLK
Healthcare · Biotechnology
$0.62
Down-$0.00 (-0.06%)
Updated Sep 29, 2026, 2:20 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · OTLK
1M range · 20 trading sessions · Daily adjusted prices
Prices through Sep 28, 2026
OTLK closed at $0.62 after 20 trading sessions, down 1.94% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 28, 2026 | $0.63 | $0.6379 | $0.6005 | $0.6211 | 6.09M |
| Sep 25, 2026 | $0.6551 | $0.6705 | $0.636 | $0.6395 | 2.94M |
| Sep 24, 2026 | $0.66 | $0.6798 | $0.6411 | $0.6558 | 2.78M |
| Sep 23, 2026 | $0.7045 | $0.7045 | $0.6617 | $0.6617 | 2.93M |
| Sep 22, 2026 | $0.6863 | $0.7137 | $0.6766 | $0.6962 | 2.86M |
| Sep 21, 2026 | $0.6853 | $0.695 | $0.6527 | $0.6863 | 2.88M |
| Sep 18, 2026 | $0.70 | $0.70 | $0.6526 | $0.6526 | 5.62M |
| Sep 17, 2026 | $0.6952 | $0.71 | $0.6775 | $0.681 | 2.81M |
| Sep 16, 2026 | $0.675 | $0.7361 | $0.662 | $0.6769 | 7.32M |
| Sep 15, 2026 | $0.64 | $0.682 | $0.6253 | $0.673 | 4.52M |
| Sep 14, 2026 | $0.6543 | $0.6688 | $0.6316 | $0.6379 | 2.85M |
| Sep 11, 2026 | $0.67 | $0.68 | $0.65 | $0.66 | 3.33M |
| Sep 10, 2026 | $0.6348 | $0.67 | $0.626 | $0.6612 | 3.11M |
| Sep 9, 2026 | $0.6397 | $0.6452 | $0.621 | $0.6439 | 2.68M |
| Sep 8, 2026 | $0.6577 | $0.67 | $0.6325 | $0.6405 | 4.81M |
| Sep 4, 2026 | $0.6599 | $0.6962 | $0.6451 | $0.6665 | 6.4M |
| Sep 3, 2026 | $0.6217 | $0.6652 | $0.6174 | $0.649 | 6.64M |
| Sep 2, 2026 | $0.62 | $0.64 | $0.6043 | $0.6263 | 4.61M |
| Sep 1, 2026 | $0.63 | $0.6408 | $0.6145 | $0.6231 | 3.58M |
| Aug 31, 2026 | $0.631 | $0.664 | $0.6276 | $0.6334 | 6.43M |
The latest Smart Investors Daily articles mentioning OTLK.
OTLK research
Company profile and research snapshot.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 11, 2026 | Ascendiant Capital | Buy | — |
| Aug 14, 2026 | BTIG | Buy | — |
| Jul 27, 2026 | BTIG | Buy | — |
| Jul 27, 2026 | HC Wainwright & Co. | Neutral | — |
| Jun 11, 2026 | Ascendiant Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 5, 2026
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today provided an update following its recent Type A
Benzinga · Feb 19, 2026
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases and Mediconsult AG, Switzerland's leading full-service
Benzinga · Feb 18, 2026
HC Wainwright & Co. analyst Douglas Tsao reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and maintains $0.5 price target.
Benzinga · Feb 17, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OTLK.
